摘要
为了对抗它可能遇到的大量感染因子,适应性免疫系统发展出极其多样化的抗体库,在早期的B细胞发育过程中,通过多个检查点消除表达多反应或自身反应抗体的B细胞,其中任何一个检查点的缺陷都可能导致多反应或自身反应性抗体的产生,并导致自身免疫性疾病。然而,最近对一组已建立的HIV-1中和抗体和大量来自hiv-1感染者的重组抗GP 160抗体的研究表明,这些抗体中有许多是多反应或自反应性的。这些抗体是在防治HIV-1感染方面发挥重要作用,还是仅仅是慢性HIV-1感染的副产品,仍有待确定。本文对HIV-1感染的适应性免疫反应异常进行了讨论,重点讨论了针对HIV-1蛋白不同抗原表位的中和抗体,并对HIV-1特异性抗体的多反应性和自反应性的功能属性进行了深入的研究。此外,我们总结了从HIV感染者中分离出的自身抗体及其与临床自身免疫性疾病的关联。最后,我们考虑的机会和缺点,利用多反应抗体从HIV感染的个人为指导策略,旨在开发有效的抗体为基础的疫苗和治疗干预艾滋病毒。了解在HIV-1感染过程中产生多反应性和自身反应性抗HIV-1抗体可能提供新的见解,这将为未来的疫苗设计奠定基础。
关键词: 人类免疫缺陷病毒1型、B细胞、多反应性抗体、自身反应性抗体、中和抗体、自身免疫性疾病。
Current Molecular Medicine
Title:Polyreactive Antibodies in Anti-HIV-1 Responses
Volume: 18 Issue: 2
关键词: 人类免疫缺陷病毒1型、B细胞、多反应性抗体、自身反应性抗体、中和抗体、自身免疫性疾病。
摘要: In order to combat the vast array of infectious agents it may encounter, the adaptive immune system develops a tremendously diversified antibody repertoire. B cells expressing polyreactive or autoreactive antibodies are eliminated through multiple checkpoints during early B cell development. Defects in any of these checkpoints may lead to the production of polyreactive or autoreactive antibodies, and cause autoimmune diseases. However, recent studies on a panel of established HIV-1-neutralizing antibodies and a large collection of recombinant anti-gp160 antibodies derived from HIV- 1-infected individuals showed that many of these antibodies are polyreactive or autoreactive. Whether these antibodies play important roles in combating HIV-1 infection or if they are merely by-products of chronic HIV-1 infection remains to be determined. In this review, we discuss the abnormalities in adaptive immune responses against HIV-1 infection with a focus on neutralizing antibodies against different antigenic epitopes of HIV-1 proteins. We also provide insight into the functional attributes of polyreactivity and autoreactivity as common and conserved features of HIV-1-specific antibodies. Furthermore, we summarize the autoantibodies isolated from HIV-infected individuals and their associations with clinical autoimmune diseases. Finally, we consider the opportunities and drawbacks of utilizing polyreactive antibodies from HIV-infected individuals to guide strategies aimed at developing effective antibody-based vaccine and therapeutic interventions for HIV. Understanding how polyreactive and autoreactive anti- HIV-1 antibodies are generated during the course of HIV-1 infection may provide new insights that will inform future vaccine design.
Export Options
About this article
Cite this article as:
Polyreactive Antibodies in Anti-HIV-1 Responses, Current Molecular Medicine 2018; 18 (2) . https://dx.doi.org/10.2174/1566524018666180720165406
DOI https://dx.doi.org/10.2174/1566524018666180720165406 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Oral Tolerance in the Treatment of Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) Nucleic Acids Modulate Autoimmunity Through Nucleic-Acid-Specific Toll-Like Receptors
Current Medicinal Chemistry Vaccination Against High Blood Pressure
Current Pharmaceutical Design Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Natural Killer T Cells as Targets for Therapeutic Intervention in Autoimmune Diseases
Current Pharmaceutical Design Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design Targeting Cytokines of the Interleukin-12 Family in Autoimmunity
Current Medicinal Chemistry Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Spots, Blots, Peaks and Chips: Proteomic Approaches in Autoimmune Diseases
Current Pharmaceutical Design Immunopathology of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy
Inflammation & Allergy - Drug Targets (Discontinued)